Research has shown that achieving maximum natural growth hormone (GH) release bythe anterior pituitary can be accomplished, in general, by combining a growth hormonereleasing hormone (GHRH) analogue with a growth hormone secretagogue receptor(GHSR) agonist. There are multiple combinations that can accomplish this goal, including combining modified GRF with ipamorelin. Of course, sometimes the goal might be to achieve more specific effects in addition to maximum GH release. in other words, by finetuning the types of GHRH agonist and GHSR agonist used, it could be possible to createmore targeted outcomes.
In the case of Modified GRF, a potent GHRH analogue, the effects go beyond simply boosting GH release. The peptide has been shown, in animal studies, to have benefits inintestinal inflammation, heart function, and wound healing1, [2], [3]
By adding ipamorelin to the mix with modified GRF, GH release is pulsed to its maximumlevel. lpamorelin, known for its specificity in boosting GH with few additional effects, hasrecently been linked to bone regrowth and matrix stabilization. These effects appear to bein addition to the bone benefits of enhanced GH release[4], [5].
Finally, it is possible to boost targeted fat burning, something that both modified GRF andipamorelin cause to a limited degree, with the aid of fragment 176-191. While technicallya GHRH agonist, fragment 176-191 has been shown in animal models to be a primaryand potent stimulator of adipocyte catabolism (fat burning). The peptide is orders ofmagnitude more potent than most GHRH agonists in stimulating fat metabolism and thusis sometimes referred to as the "lipolytic fragment." Adding fragment 176-191 to the mix isa way to boost fat burning, particularly in the setting of enhanced GH release, and shiftmetabolism toward the accumulation of lean body mass[8].
About The Author
The above literature was researched, edited and organized by Dr. Logan, M.D. Dr. Logarholds a doctorate degree from Case Western Reserve University School of Medicine anca B.S.in molecular biology.
Scientific JournaAuthor
been listed as a noteworthy Chemist, researcher by Marquis Who'sDr. Jan lzdebski hasMaster of Science from University Warsaw, Poland, 1959 and is a Who. He attained a Doctor of Philosoph,University Warsaw, Poland, 1965, along with a Doctor of Science,University Warsaw,oland, 1979.He studied how GRF 1-29 is more resistant toenzymatic degradaton and how that affects its half-life.
Dr. Jan lzdebski iseing referenced as one of the leading scientists involved in theresearch and develpment of GRF 1-29.In no way is this doctor/scientist endorsing oradvocating the purcase, sale, or use of this product for any reason. There is no affiliationor relationship, imped or otherwise, between PEPTIDE GURUS and this doctor. Thepurpose of citing thedoctor is to acknowledge, recognize, and credit the exhaustivepment efforts conducted by the scientists studying this peptide. Dr.research and devel Jan lzdebski is listein [9]under the referenced citations.
Resources
1.T. lto et al., “Gl side-effects of a possible therapeutic GRF analogue in monkeysare likely due to VlP receptor agonist activity," Peptides, vol. 22,no.7, pp. 1139-1151.Jul. 2001.[PubMed]
2.M.Waelbroeck,P.Robberecht, D.H. Coy, J.-C.Camus, P. D. Neef, and J.Christophe, “Interaction of Growth Hormone-Releasing Factor (GRF) and 14 GRFAnalogs with Vasoactive Intestinal Peptide (VP) Receptors of Rat Pancreas.Discovery of(N-Ac-Tyr1,D-Phe2)-GRF(1-29)-NH2 as a VlP Antagonist,Endocrinology,vol.116,no.6, pp.2643-2649,Jun.1985.[PubMed]
3.A.V. Schally,X.Zhang,R.Cai, J.M.Hare, R. Granata, and M. Bartoli, “Actionsand potential therapeutic applications ot arowth hormone-releasina hormoneagonists,” Endocrinology. [PubMed]
4.N.B.Andersen,K.Malmlöf, P.B. Johansen,T. T. Andreassen, G. Ørtoft, and H.Oxlund,“The qrowth hormone secretagogue ipamorelin counteracts glucocorticoid.induced decrease in bone formation of adult rats," Growth Horm, lGF Res, Off J.Growth Horm.Res.Soc.Int.IGF Res.Soc., vol.11,no.5,pp.266-272, 0ct. 2001[PubMed]
5.Svensson et al., “The GH secretagogues ipamorelin and GH-releasing peptide-6increase bone mineral content in adult female rats,” J. Endocrinol.. vol. 165. no. 3.pp.569-577,Jun.2000.[PubMed]
6.M. Heffernan et al., “The Effects of Human GH and lts Lipolytic Fragment(AOD9604) on Lipid Metabolism Following Chronic Treatment in Obese Mice andB3-AR Knock-Out Mice,"Endocrinology, vol. 142,no.12, pp.5182-5189, Dec.2001.[PubMed]
7.R. Ferrer-Lorente, C. Cabot, J.-A. Fernández-López, and M. Alemany, “Combinedeffects of oleoy-estrone and a beta3-adrenergic agonist (CL316,243) on lipidstores of diet-induced overweight male Wistar rats,” Life Sci., vol. 77, no. 16, pp.2051-2058,Sep.2005.[PubMed]
8.F. M. Ng, J.Sun, L. Sharma, R. Libinaka, W. J. Jiang, and R. Gianello, “Metabolicstudies of a synthetic lipolytic domain (AOD9604) of human growth hormone,Horm.Res., vol.53, no.6, pp.274-278,2000.[PubMed]
9.Izdebski, J., et al. “Potent Trypsin-Resistant HGH-RH Analogues.” Journa/ of PEPTIDE GURUS :An Oficial Publication of the European Peptide Society, 200410.1002/PSC.563.[Semantics Scholar]
ALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE AREFOR INFORMATIONAL AND EDUCATIONAL PURPOSES ONLY.
The products offered on this website are furnished for in-vitro studies only. in-vitro studies(Latin: in glass) are performed outside of the body. These products are not medicines ordrugs and have not been approved by the FDA to prevent, treat or cure any medicalcondition, ailment or disease. Bodily introduction of any kind into humans or animals isstrictly forbidden by law.
